Filing Flows › PTC Therapeutics (PTCT) › Guidance & outlook
PTC Therapeutics (PTCT) guidance and outlook
PTC Therapeutics (PTCT) raised its guidance on Oct 29, 2026: Revenue $1.3B for FY2026.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $1.3B | raised |
| Revenue | FY2026 | $960M–$990M | raised |
| Stock-based compensation | FY2026 | $95.0M | new |
From the earnings release filed Oct 29, 2026 (8-K on EDGAR).
PTC Therapeutics' latest quarter
PTC Therapeutics, Q3 2026: revenue $358M (+70% year over year), operating margin 7.0%, net loss $51.7M, operating cash flow −$25.3M. The chart follows the revenue to costs, profit and cash.
Questions
Did PTC Therapeutics raise or lower its guidance?
PTC Therapeutics (PTCT) raised its guidance on Oct 29, 2026: Revenue $1.3B for FY2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.